Results 11 to 20 of about 29,030 (239)

Comparative effectiveness of natalizumab ocrelizumab in multiple sclerosis: a real-world propensity score–matched study

Therapeutic Advances in Neurological Disorders, 2022
Background: For treatment of relapsing-remitting multiple sclerosis (RRMS), a broad range of disease-modifying therapies (DMT) is available. However, few comparative effectiveness studies between different drugs have been performed.
Katrin Pape, Leoni Rolfes, Falk Steffen, Muthuraman Muthuraman, Melanie Korsen, Sven G. Meuth, Frauke Zipp, Stefan Bittner   +7 more
doaj   +2 more sources

Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses

Frontiers in Neurology, 2021
Background: Plasma concentration of natalizumab falls above the therapeutic threshold in many patients who, therefore, receive more natalizumab than necessary and have higher risk of progressive multifocal leukoencephalopathy.Objective: To assess in a ...
Jose M. Serra López-Matencio, Yaiza Pérez García, Virginia Meca-Lallana, Raquel Juárez-Sánchez, Angeles Ursa, Lorena Vega-Piris, Dora Pascual-Salcedo, Annick de Vries, Theo Rispens, Cecilia Muñoz-Calleja, Cecilia Muñoz-Calleja   +10 more
doaj   +2 more sources

Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation

Frontiers in Immunology, 2021
ObjectiveTo determine the transfer of the monoclonal antibody natalizumab into breastmilk and to evaluate drug and serum neurofilament light chain ((s)NfL) levels in natalizumab exposed pregnancies and lactation periods.MethodsEleven women with relapsing
Undine Proschmann, Rocco Haase, Hernan Inojosa, Katja Akgün, Tjalf Ziemssen   +4 more
doaj   +2 more sources

A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis

Annals of Clinical and Translational Neurology
Objective No direct comparisons of the effect of natalizumab and ocrelizumab on progression independent of relapse activity (PIRA) and relapse‐associated worsening (RAW) events are currently available.
Pietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, Damiano Paolicelli, Emilio Portaccio, Matilde Inglese, Matteo Foschi, Francesco Patti, Franco Granella, Silvia Romano, Paola Cavalla, Giovanna De Luca, Paolo Gallo, Paolo Bellantonio, Antonio Gallo, Sara Montepietra, Alessia Di Sapio, Marika Vianello, Rocco Quatrale, Daniele Spitaleri, Raffaella Clerici, Valentina Torri Clerici, Eleonora Cocco, Vincenzo Brescia Morra, Girolama Alessandra Marfia, Vincenzo Daniele Boccia, Massimo Filippi, Maria Pia Amato, Maria Trojano, the Italian MS Register   +29 more
doaj   +2 more sources

High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients

Therapeutic Advances in Neurological Disorders, 2021
Aims: To retrospectively assess factors associated with John Cunningham virus (JCV) seroconversion in natalizumab-treated patients. Background: Natalizumab is highly effective for the treatment of relapsing–remitting multiple sclerosis (RRMS), but its ...
Christopher M. Dwyer, Vilija G. Jokubaitis, Jim Stankovich, Josephine Baker, Jodi Haartsen, Helmut Butzkueven, Adriana Cartwright, Neil Shuey, Yara Dadalti Fragoso, Louise Rath, Olga Skibina, Kylie Fryer, Ernest Butler, Jennifer Coleman, Jennifer MacIntrye, Richard Macdonell, Anneke van der Walt   +16 more
doaj   +2 more sources

CD56^brightNK cells are negatively associated with antibody response to vaccination in people with multiple sclerosis on B-cell-depleting therapy. [PDF]

Clin Transl Immunology
Antibody response to vaccination in people with multiple sclerosis receiving B‐cell depletion therapy is associated with B‐cell frequency but not time since B‐cell depletion. Immunoregulatory CD56bright NK cells may negatively impact antibody responses in this group.
Perkins GB, Hope CM, Chai CS, Tunbridge MJ, Sterling S, Webb K, Yap J, Yeow AEL, Masavuli MG, Scaffidi J, Zuiani JD, Akerman A, Aggarwal A, Milogiannakis V, Roberts MB, Hurtado PR, Turville S, Grubor-Bauk B, Barry SC, Ravindran J, Coates PT, Hissaria P.   +21 more
europepmc   +2 more sources

A National Danish Effectiveness Study of Ocrelizumab Versus Natalizumab in Multiple Sclerosis. [PDF]

Eur J Neurol
This was a national multicenter comparative effectiveness research study using data from the Danish Multiple Sclerosis Registry. Relapsing–remitting multiple sclerosis patients initiating ocrelizumab or natalizumab between January 2018 to April 2023 were included.
Maersk-Moller C, Pontieri L, Stilund MLM, Christensen JR, Storr LK, Hansen V, Schäfer J, Weglewski A, Romani KQ, Jensen HB, Illes Z, Papp V, Sejbaek T, Poulsen MB, Kant M, Torring CW, Sellebjerg F, Magyari M, DMSG Group.   +18 more
europepmc   +2 more sources

Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.

JAMA Neurology, 2023
Importance Autologous hematopoietic stem cell transplant (AHSCT) is available for treatment of highly active multiple sclerosis (MS). Objective To compare the effectiveness of AHSCT vs fingolimod, natalizumab, and ocrelizumab in relapsing-remitting MS ...
T. Kalincik, S. Sharmin, I. Roos, M. Freedman, H. Atkins, J. Burman, J. Massey, I. Sutton, Barbara Withers, Richard Macdonell, A. Grigg, Øivind Torkildsen, L. Bø, A. K. Lehmann, E. Havrdová, E. Krasulová, M. Trněný, T. Kozák, A. van der Walt, H. Butzkueven, P. Mccombe, O. Skibina, J. Lechner-Scott, B. Willekens, E. Cartechini, S. Ozakbas, R. Alroughani, J. Kuhle, F. Patti, P. Duquette, A. Lugaresi, S. Khoury, M. Slee, R. Turkoglu, S. Hodgkinson, N. John, D. Maimone, M. Sá, V. van Pesch, O. Gerlach, G. Laureys, L. Van Hijfte, R. Karabudak, D. Spitaleri, T. Csépány, R. Gouider, T. Castillo-Triviño, B. Taylor, B. Sharrack, J. Snowden, S. Mrabet, J. Garber, J. Sánchez-Menoyo, E. Aguera-Morales, Y. Blanco, A. Al-Asmi, B. Weinstock-Guttman, Y. Fragoso, K. de Gans, A. Kermode   +59 more
semanticscholar   +1 more source

Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis

JAMA Neurology, 2023
This randomized clinical trial evaluates matching efficacy, safety, and immunogenicity between biosimilar natalizumab and reference natalizumab in patients with relapsing-remitting multiple sclerosis.
B. Hemmer, H. Wiendl, Karsten Roth, Hendrik Wessels, J. Höfler, C. Hornuss, B. Liedert, K. Selmaj   +7 more
semanticscholar   +1 more source

Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.

JAMA Neurology, 2023
Importance Natalizumab cessation is associated with a risk of rebound disease activity. It is important to identify the optimal switch disease-modifying therapy strategy after natalizumab to limit the risk of severe relapses.
Chao Zhu, T. Kalincik, D. Horáková, Zhen Zhou, K. Buzzard, O. Skibina, R. Alroughani, Guillermo Izquierdo, S. Eichau, J. Kuhle, F. Patti, F. Grand'Maison, S. Hodgkinson, P. Grammond, J. Lechner-Scott, E. Butler, A. Prat, M. Girard, P. Duquette, R. Macdonell, B. Weinstock-Guttman, S. Ozakbas, M. Slee, M. Sá, V. van Pesch, M. Barnett, B. Van Wijmeersch, O. Gerlach, J. Prevost, M. Terzi, C. Boz, G. Laureys, L. Van Hijfte, A. Kermode, J. Garber, B. Yamout, S. Khoury, Daniele Merlo, M. Monif, V. Jokubaitis, A. van der Walt, H. Butzkueven   +41 more
semanticscholar   +1 more source